Cannabis Bioscience International Holdings, Inc.

OTCPK:CBIH Stock Report

Market Cap: US$6.3m

Cannabis Bioscience International Holdings Valuation

Is CBIH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CBIH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CBIH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CBIH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CBIH?

Key metric: As CBIH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CBIH. This is calculated by dividing CBIH's market cap by their current revenue.
What is CBIH's PS Ratio?
PS Ratio17.8x
SalesUS$354.91k
Market CapUS$6.33m

Price to Sales Ratio vs Peers

How does CBIH's PS Ratio compare to its peers?

The above table shows the PS ratio for CBIH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
APDN Applied DNA Sciences
2.3x37.5%US$7.8m
IPA ImmunoPrecise Antibodies
0.6x19.7%US$10.8m
PBSV Pharma-Bio Serv
1.1x53.3%US$11.5m
RSCF Reflect Scientific
2.4xn/aUS$4.1m
CBIH Cannabis Bioscience International Holdings
17.8xn/aUS$6.3m

Price-To-Sales vs Peers: CBIH is expensive based on its Price-To-Sales Ratio (17.8x) compared to the peer average (1.6x).

Price to Sales Ratio vs Industry

How does CBIH's PS Ratio compare vs other companies in the US Life Sciences Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.6x2.4%US$1.77b
ATLN Atlantic International
0.6xn/aUS$259.76m
NOTV Inotiv
0.2x7.5%US$93.35m
SNCE Science 37 Holdings
0.6x17.5%US$34.67m
CBIH 17.8xIndustry Avg. 3.2xNo. of Companies10PS02.85.68.411.214+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CBIH is expensive based on its Price-To-Sales Ratio (17.8x) compared to the US Life Sciences industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is CBIH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CBIH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio17.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CBIH's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

2.5%

1Y

15.9%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

7D

3.0%

1Y

11.4%